Compound A Antitumor Agent for Biliary Tract Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for biliary tract cancer, including chemotherapy, have insufficient therapeutic effects and high recurrence rates, with no established antitumor agents specifically targeting this aggressive form of cancer.
Innovation Solution
The use of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine (Compound A) or its salt/prodrug as an antitumor agent, administered via injection, with a specific dosing regimen of 20 mg/m2 or more, once a week for three weeks, followed by a week of cessation, targeting bile duct cancers including extrahepatic and intrahepatic types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used for biliary tract cancer, then treatment can be provided to inoperable or recurrence cases, but the therapeutic effects are insufficient and recurrence rate remains high
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of cytosine to create Compound A (1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine), which has enhanced antitumor activity specifically against biliary tract cancer. This structural modification transforms conventional chemotherapy into a more effective treatment with improved therapeutic effects and reduced recurrence rates in clinical cases.
2Reliability
If surgical resection is performed for biliary tract cancer, then complete cure can be achieved, but the recurrence rate is still high
Solution Approach 1:
The patent applies preliminary action by administering Compound A chemotherapy treatment before or after surgical resection to eliminate micrometastatic disease and prevent recurrence. This adjuvant therapy approach addresses the high recurrence rate following surgery by proactively treating residual cancer cells that surgery cannot remove.
3Reliability
If biliary tract cancer is detected at early stage, then prognosis can be improved, but the cancer has very few clinical symptoms at early stage making detection difficult
Solution Approach 1:
The patent applies copying by using Compound A to target and destroy cancer cells that may have spread microscopically after surgical resection, even when these cells are not detectable by conventional imaging or clinical examination. This molecular-level targeting allows treatment of undetectable residual disease, improving prognosis for early-stage patients.
Data Source
AI summary
It is an object of the present invention to provide an antitumor agent for biliary tract cancer that exhibits effects on biliary tract cancer, and a method for treating biliary tract cancer. According to the present invention, provided is an antitumor agent for biliary tract cancer, comprising 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine, a salt thereof, or a prodrug thereof.